Avid Bioservices Inc (CDMO)

[biopharm]

Is this Xencor Xmab5871 infringing upon PS Targeting IP rights? I say YES and this is why we must ask the new BODs to make damn sure they protect the IP assets and KNOWING the details of Steve Demattos departure, his confidentiality agreement, his deposition in relation to the sabotage by CSM who had CEO Gerald Finken and his sidekick Jeanette Bleecker that we know already admitted swapping and sabotaging the Peregrine trial....is critical to realizing the true value of the PS Targeting IP at Peregrine, now called Avid Bioservices.

Ask the new BODs why they are not getting all this information and making it known to the public and all shareholders.....as they can't keep it a secret when they get requests via certified letters.

XmAb5871 is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target Fc?RIIb, a receptor that inhibits B cell function. XmAb5871 is the first drug candidate to our knowledge that targets Fc?RIIb inhibition.

Yes, Xencor to their knowledge MAY now know PS Targeting rights are being infringed upon....

If everyone does not resend certified letters and question EVERYTHING ....then we will see breadcrumb nothing in return for the sale or license of the PS Targeting platform

Seek the answers

Now

Wow....now we have Xmab7195 which may be a secondary ...downstream mechanism of action, as a result of upstream, global....PS Targeting and again, I have not seen the new BODs make no public announcement about them confirming with any KOLs, like Dr Jedd Wolchok ...etc to validate the PS Targeting IP and verify any infringements against PS Targeting IP, like that of Xmab7195 by Xencor! (Where ex Peregrine employee Steve Demattos is now employed...)

XmAb7195
Completed a Phase 1a clinical trial in healthy subjects and atopic subjects with high IgE levels; Entered Phase 1 trial for subcutaneous formulation in 2016.

XmAb7195 targets IgE with its variable domain, and uses the XmAb immune inhibitor Fc domain to target Fc?RIIb, resulting in three distinct mechanism of action for reducing IgE levels. By comparison, the only marketed antibody to control IgE in severe asthma, omalizumab, has only one mechanism of action: blocking IgE receptor binding. It does not clear IgE from the circulation or prevent IgE production.

Here is what the new BODs must take action....get those second and third set of letters in ..NOW

Mechanism of phosphatidylserine inhibition of IgE/FceRI-dependent anaphylactic human basophil degranulation via CD300a.
https://www.ncbi.nlm.nih.gov/m/pubmed/24815424/